In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...

Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...

India's healthtech space is expected to witness disruption as weight loss drugs Ozempic and Mounjaro enter the market through ...

The restaurant industry may face significant changes due to new weight loss drugs like Ozempic and Mounjaro, which lead to ...

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...

Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

Omada Health is launching new AI tools for nutrition care after filing its S-1 to go public.

Ozempic and Wegovy maker Novo Nordisk ... Eli Lilly shares were up 2.6% after the news. “The changes are made in light of the recent market challenges Novo Nordisk has been facing, and the ...

Novo Nordisk CEO Lars Fruergaard Jorgensen is stepping down per mutual agreement with the company. The company said Friday he ...

Indian market for these drugs has grown to nearly Rs 600 crore and is expected to keep growing. Weight-loss drugs are ...